VEEV · Veeva Systems

S&P 500 #348 · NYSE

Risiko 6/10 · Life Sciences SaaS – Moderate-High Risk · $201.20 ▲ 3.47%

Kennzahlen

Price $201.20
Market cap $32.7B
P/E (ttm) 35.67
Div yield none
52-wk range $148.05 – $310.50
Index rank #348 / —

Wichtigste Risiken

Stock 45% below 52-week high – sentiment/growth re-rating (Equity market) — HIGH
Life sciences R&D budget cuts by pharma clients (Pharma/biotech industry) — MED
Single-industry concentration in life sciences (Sector concentration) — MED
Competitive pressure from Salesforce, Verint in CRM (Technology rivals) — LOW

Fazit

Cloud CRM and data platform purpose-built for life sciences; dominant in pharma/biotech but stock has re-rated sharply lower amid sector headwinds and growth concerns.

Interaktive Analyse öffnen →

Recherche, keine Anlageberatung.